Naarden, NL, 16 December 2020 – Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, today announces the publication of two articles in the peer-reviewed journal, The Journal of Huntington’s Disease, highlighting positive efficacy and safety data for pridopidine, as demonstrated by new additional analyses of the Phase 2 PRIDE-HD and Open-HART trials.
Pridopidine is a first-in-class small molecule in development for the treatment of Huntington’s disease (HD) and Amyotrophic Lateral Sclerosis (ALS). It is the most selective, high-affinity Sigma-1-receptor (S1R) agonist in clinical development. Activation of the S1R by pridopidine exerts neuroprotective effects in preclinical models of HD and other in neurodegenerative diseases.
Highlights from the published articles include the following:
Andrew McGarry, MD, Director, Clinical Development, Clintrex and lead author of the PRIDE-HD and Open-HART publications, commented:
“Pridopidine has demonstrated an excellent long-term safety profile and suggestion of improvement in clinical trials, as well as in exploratory analyses, where early HD populations appear to particularly benefit. In view of these promising data, the newly initiated Phase 3 study in HD will be of great interest to the entire HD community."
Pridopidine is an orally administered drug currently being assessed in a Phase 3 randomized, double-blind, placebo-controlled study (PROOF-HD), evaluating the effect of pridopidine 45 mg bid on Total Functional Capacity (TFC) in patients with early stage HD. The first patients in this trial were dosed in October 2020. TFC is the standard widely used clinical scale for tracking the progression of HD with respect to functional capacity. In addition, TFC is accepted by the FDA and EMA as a single primary endpoint in HD trials. Pridopidine is also being assessed in the first ever platform trial for ALS in collaboration with the Healey Center for ALS at Mass General Hospital.
Ralf Reilmann, MD, Founding Director of the George Huntington Institute and Principal Investigator of the PROOF-HD Phase 3 clinical trial in Europe, commented:
“These are critical results. At the 45 mg bid dosage used in the Phase 2 Pride-HD and Open-HART trials, pridopidine is the first drug to show a significant clinical effect on the functional decline caused by Huntington’s disease progression, as well as long-term safety data. The PROOF-HD Phase 3 trial will be an important next step to see if pridopidine can offer an effective and safe treatment that allows patients to better maintain their functional and motor abilities, and quality of life.”
Michael R. Hayden, MD, PhD, CEO of Prilenia and world-renowned expert in Huntington’s Disease research, commented:
“Pridopidine is showing strong scientific and clinical data in support of its use for Huntington’s disease and other neurodegenerative diseases, such as ALS. By understanding the mechanism of action clearly, we are now delighted about the reported positive data in terms of efficacy and safety.”
Further details of the ongoing PROOF-HD trial can be found here:
About Prilenia (www.prilenia.com)
Prilenia is a clinical stage biotech startup founded in 2018 with the purpose of improving the lives of patients and their families by developing treatments for neurodegenerative and neurodevelopmental disorders. Prilenia raised $ 88.5 million thus far and is backed by a group of well-respected investors: Talisman, Forbion, Morningside, Sectoral and ALS Investment Fund. The Company is based in Naarden, the Netherlands, Herzliya, Israel and Boston, MA in the U.S.
Prilenia’s lead asset is Pridopidine, a first-in-class drug candidate with an established safety profile and therapeutic potential in several neurodegenerative diseases affecting adults and children. The highly selective S1R agonist was acquired from Teva in 2018.
Pridopidine’s favorable safety profile has been established in clinical trials in >1300 study participants, exposed to various doses for a total of ~1300 patient years.
Pridopidine for Huntington’s Disease
HD is a fatal, inherited, neurodegenerative disorder. Every offspring of an HD patient has a 50% chance of inheriting the gene. Usually starting at around 40 years of age, HD patients suffer from movement disorder, progressive functional and cognitive decline, psychiatric disturbances and behavioral symptoms. Following diagnosis, functional, motor and cognitive functions decline steadily, ultimately leading to immobility, dementia and premature death.
Pridopidine has demonstrated maintenance of functional capacity in HD patients, as measured by Total Functional Capacity (TFC), in a clinical trial. This effect was most prominent in early stage HD patients (HD1 and HD2), who showed functional benefit from pridopidine 45 mg, taken twice a day.
There is extensive preclinical evidence that further supports pridopidine’s potential beneficial effect in HD. The therapeutic effect has been shown to be mediated exquisitely by the sigma-1 receptor (S1R) using multiple deletion and antagonist models.
Prilenia has an orphan drug designation for pridopidine for the treatment of HD in both the US and Europe.
PROOF-HD is a Phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of pridopidine in patients with early stage of Huntington’s Disease. The purpose of the study is to evaluate the effect of pridopidine 45mg bid on functional capacity, as well as on motor and behavioral features.
For more information please contact: firstname.lastname@example.org